Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.
about
Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disordersHomogeneous Biosensing Based on Magnetic Particle LabelsDifferential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic markerPotential applications of magnetic particles to detect and treat Alzheimer's disease.Quantitative analysis of total β-subunit of human chorionic gonadotropin concentration in urine by immunomagnetic reduction to assist in the diagnosis of ectopic pregnancyPlatelet dysfunction in hypercholesterolemia mice, two Alzheimer's disease mouse models and in human patients with Alzheimer's disease.Assaying Carcinoembryonic Antigens by Normalized Saturation Magnetization.Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles.Plasma tau in Alzheimer disease.Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer's Disease.Repetitive head impact exposure and later-life plasma total tau in former National Football League players.Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults.On comparing 2 correlated C indices with censored survival data.Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress.Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.The Study of Postmortem Human Synaptosomes for Understanding Alzheimer's Disease and Other Neurological Disorders: A Review.Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseasesQuantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood.Increased levels of plasma total tau in adult Down syndrome.Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease.Plasma Aβ analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder.Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease.Eight-Channel AC Magnetosusceptometer of Magnetic Nanoparticles for High-Throughput and Ultra-High-Sensitivity Immunoassay.A Blood Test for Alzheimer's Disease: Progress, Challenges, and Recommendations.The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease.
P2860
Q26741861-332AB829-98FC-4E76-B0FE-D9B3F8EBE0EFQ26747505-D4E8AA44-A394-477E-883B-3F74685EE03EQ27339637-EDD44AA7-BED5-46A2-B538-C485B70D4634Q34289125-BEF35FE8-BCBC-4583-8402-43D5E23D7670Q35284593-535533A7-0D52-409B-982B-2A1C831C5D14Q35804607-0E3098D3-6E2B-44BE-BC73-761C578F69A6Q35848988-D4C56E14-0C5D-4358-8FBA-38F7D02E5A2DQ36982173-AB26778C-A879-4EB9-81B2-8249D21556ECQ37384690-3D82DE19-422E-49C5-8894-9692EAE144D5Q37588576-D23A08B0-17A2-4B0B-B957-E2E4CB77E88EQ37645272-8B96C907-8CBC-4D84-BC60-9C172D43901FQ37681181-38B5A1C7-4CAA-4589-A9DF-BE10C31130A9Q38652465-87DDE613-24B7-4127-A968-02E77DF1E5C2Q38980003-D551C15A-75B8-48FB-9E97-7FA6EB743961Q39451605-04C51313-CAA0-4AD6-9AC3-E6536ADDD3ACQ39451611-C27EF9AE-E1B2-4058-BE58-A52BCA35FC09Q39451622-724B898E-190C-446F-A82F-82A3DE376CB4Q40129154-7CDB2207-272F-4C9B-A7FB-08122B136E0FQ41097447-623045EC-ED17-4683-B210-54C5432995CAQ41518367-30CD3128-D9FA-4B0A-89E6-2EF32218C130Q41600844-D23D2104-E26B-466A-8CAD-5FA20815AC9FQ42252548-50B57A62-6070-4646-AE7E-2FE3832C3149Q47143134-9F461978-32A9-43ED-ABE0-D96EE819DA32Q48450061-79462B7A-3FF9-4DB3-987D-89E16ADE8222Q50050458-1E1D8661-89AA-40B9-9946-B7A699F7E6C2Q50753131-E60A4539-79E9-44EE-B4FB-D197F712DEA8Q51732196-06E83B86-FA56-48B6-90C5-67285CE91BB4Q52609763-BBD82C49-1739-4C4D-9F1D-8D60BB1B13BBQ55437462-2BF950A5-0216-476C-B890-2F75DB89CA7F
P2860
Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined plasma biomarkers for ...... rment and Alzheimer's disease.
@en
Combined plasma biomarkers for ...... rment and Alzheimer's disease.
@nl
type
label
Combined plasma biomarkers for ...... rment and Alzheimer's disease.
@en
Combined plasma biomarkers for ...... rment and Alzheimer's disease.
@nl
prefLabel
Combined plasma biomarkers for ...... rment and Alzheimer's disease.
@en
Combined plasma biomarkers for ...... rment and Alzheimer's disease.
@nl
P2093
P2860
P356
P1476
Combined plasma biomarkers for ...... irment and Alzheimer's disease
@en
P2093
Che-Chuan Yang
Chia-Shin Ho
Chin-Yih Hong
Hao Chun Liu
Herng-Er Horng
Hong-Chang Yang
Hsin-Hsien Chen
Shieh-Yueh Yang
Shuo-Fen Chang
Ta-Fu Chen
P2860
P304
P356
10.1021/CN400129P
P577
2013-10-23T00:00:00Z